Natural killer cells in hepatitis C virus recurrence following liver transplantation: What role do they play?

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 4, 2009, Pages 329-332

  de Arias, Alejandro Espadas ^a   Haworth, Simone Elizabeth ^a   Defeo, Tullia Maria ^a   Poli, Francesca ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; VIRUS RNA;

ALLOIMMUNITY; EDITORIAL; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NATURAL KILLER CELL; RECURRENT DISEASE; RISK FACTOR;

GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECEPTORS, KIR; RECURRENCE; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70049086218     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.29     Document Type: Editorial

References (38)

1. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat. Immunol. 3(1), 6-8 (2002).
2. Krug A, French AR, Barchet W et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21(1), 107-119 (2004).
3. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 20(1), 217-251 (2002).
4. Mandelboim O, Reyburn HT, Vales-Gomez et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J. Exp. Med. 184(3), 913-922 (1996).
5. Falk CS, Schendel DJ. HLA-C revisited. Ten years of change. Immunol. Res. 16(2), 203-214 (1997).
6. Pende D, Biassoni R, Cantoni C et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J. Exp. Med. 184(2), 505-518 (1996).
7. Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin. Exp. Immunol. 109(3), 451-457 (1997).
8. Bonavita MS, Franco A, Paroli et al. Normalization of depressed natural killer activity after interferon-α therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int. J. Tissue React. 15(1), 11-16 (1993).
9. + natural killer T cells in chronic hepatitis C viral infection. J. Hepatol. 37(1), 101-108 (2002).
10. + T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 32(5), 962-969 (2000).
11. Yamagiwa S, Matsuda Y, Ichida T et al. Sustained response to interferon-α plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol. Res. 38(7), 664-672 (2008).
12. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (5685), 872-874 (2004).
13. Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr. Top. Microbiol. Immunol. 298, 225-257 (2006).
14. Lopez-Vazquez A, Rodrigo L, Martinez-Borra J et al. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulinlike receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Infect. Dis. 192(1), 162-165 (2005).
15. Paladino N, Flores AC, Marcos CY et al. Increased frequencies of activating natural killer receptors are associated with liver injury in individuals who do not eliminate hepatitis C virus. Tissue Antigen 69(Suppl. 1), 109-111 (2007).
16. Rauch A, Laird R, McKinnon E et al. The Swiss HIV Cohort Study. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigen 69(Suppl. 1), 237-240 (2007).
17. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558-567 (2005).
18. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J. Hepatol. 35(5), 666-678 (2001).
19. Oertel M, Kohlhaw K, Diepolder HM et al. Alloreactivity of natural killer cells in allogeneic liver transplantation. Transplantation 72(1), 116-122 (2001).
20. Bishara A, Brautbar C, Zamir G, Eid A, Safadi R. Impact of HLA-C and Bw epitopes disparity on liver ransplantation outcome. Hum. Immunol. 66(11), 1099-1105 (2005).
21. Hanvesakul R, Spencer N, Cook M et al. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation. Am. J. Transplant. 8(9), 1931-1941 (2008).
22. Shen K, Zheng SS, Park O, Wang H, Sun Z, Gao B. Activation of innate immunity (NK/IFN-γ) in rat allogeneic liver transplantation: contribution to liver injury and suppression of hepatocyte proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 294(4), G1070-G1077 (2008).
23. Tran TH, Middleton D, Döhler B et al. Reassessing the impact of donor HLA-C genotype on long-term liver transplant survival. Am. J. Transplant. DOI: 10.1111/j.1600-6143.2008.02341.x (2009).
24. Espadas de Arias A, Haworth SE, Belli et al. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl. 15(4), 390-399 (2009).
25. Davis GL. Chronic hepatitis C and liver transplantation. Rev. Gastroenterol. Disord. 4(1), 7-17 (2004).
26. Feray C, Caccamo L, Alexander GJ et al.; European Concerted Action on Viral Hepatitis (EUROHEP) Group. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 117(3), 619-625 (1999).
27. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28(3), 823-830 (1998).
28. + innate lymphocyte populations associated with severity of hepatitis C recurrence. Liver Transpl. 14(1), 31-40 (2008).
29. Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl. 12(3), 363-372 (2006).
30. Ciccorossi P, Maina AM, Oliveri F. et al. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis. Liver Int. 27(5), 612-619 (2007).
31. Massaguer A, Ramírez S, Carrión JA et al. Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. Am. J. Transplant. 7(9), 2172-2179 (2007).
32. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161(2), 571-577 (1998).
33. Bonorino P, Leroy V, Dufeu-Duchesne T et al. Features and distribution of CD8 T cells with human leukocyte antigen class I-specific receptor expression in chronic hepatitis C. Hepatology 46(5), 1375-1386 (2007).
34. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 46(5), 1350-1356 (2007).
35. Rosen HR, Chou S, Corless CL et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 64(5), 721-726 (1997).
36. Belli LS, Burra P, Poli F et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 130(3), 695-702 (2006).
37. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36(1), 202-210 (2002).
38. McCaughan GW, Shackel NA, Bertolino P, Bowen DG. Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation 87(8), 1105-1111 (2009).